Loading...

Home
Stock
AXSM

AXSM News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Forecast Technical Valuation Financials Earnings Should I Buy News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
All US Stocks

AI Strategies

AI Stock Picker
Swing Trading
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Monitor News

Compare

TradingView
SeekingAlpha

AXSM News

CommVault and Axsome Options Trading Activity Surges

2 days agoNASDAQ.COM

Piper Sandler Raises Axsome Therapeutics (AXSM) Price Target to $223, Optimistic on Alzheimer’s Drug Potential

Jan 23 2026Yahoo Finance

Axsome Therapeutics (AXSM) Projects $638.5M Revenue in 2025, $507.1M from Auvelity

Jan 17 2026stocktwits

Axsome Therapeutics (AXSM) Projects $638.5M Revenue for 2025, 66% Growth

Jan 12 2026NASDAQ.COM

Axsome Therapeutics (AXSM) Reports Q4 2025 Net Revenue of ~$196M, 65% Y/Y Growth

Jan 12 2026seekingalpha

Axsome and Exelixis: New Investment Opportunities in Biotech

Jan 08 2026Fool

Axsome and Exelixis Show Significant Revenue Growth in Biotech Sector

Jan 08 2026NASDAQ.COM

Axsome Therapeutics Director Mark E Saad Sells 37,577 Shares for $6 Each

Jan 05 2026Yahoo Finance

AXSM Events

an image of No data

No data

AXSM Monitor News

Axsome Therapeutics projects strong revenue growth and FDA expansion for Auvelity

Axsome Therapeutics projects $638.5M revenue for 2025, driven by AUVELITY sales

Axsome Therapeutics receives FDA Priority Review for AXS-05

AXSM Earnings Analysis

Axsome Therapeutics Inc Reports Third Quarter 2024 Financial Results

People Also Watch